Company Description
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases.
The company develops cell-targeted lipid nanoparticle, or ctLNP platform. ctLNP delivery system is designed to address the limitations of existing technologies and comprises three elements.
First, LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen.
Second, identify and refine a small format targeting ligand against a receptor uniquely expressed on the target cell to achieve highly potent and selective delivery to specific tissues and cell types of interest.
Finally, bioconjugated linkers that facilitate modular attachment of the targeting ligands to the core stealth LNP; and novel immune-quiet DNA (iqDNA) enable long-lasting high levels of gene expression from non-integrating episomes and avoid innate immune sensors that have long prevented DNA from use in non-viral systems.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Cameron McDonough |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 655 7500 |
| Website | generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001733294 |
| CUSIP Number | 37148K100 |
| ISIN Number | US37148K1007 |
| Employer ID | 81-4301281 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | President, Chief Executive Officer and Director |
| Yalonda Howze J.D. | Chief Legal Officer and Secretary |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Kevin John Conway | Chief Financial Officer |
| Antoinette Paone M.B.A., M.S. | Chief Operating Officer |
| Jasmin Tower | Chief Human Resources Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Scientific Officer |
| Caitlin Cooper M.B.A. | Senior Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 6, 2025 | 8-K | Current Report |
| Jan 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |